Passionflower for Anxiety Relief

In the landmark Akhondzadeh 2001 randomized double-blind trial published in the Journal of Clinical Pharmacy and Therapeutics, 36 outpatients with generalized anxiety disorder (GAD) were assigned to either passionflower extract (45 drops/day) or oxazepam 30 mg/day. After four weeks, both treatments produced statistically equivalent reductions in Hamilton Anxiety Rating Scale scores — passionflower matched the benzodiazepine on the primary anxiolytic endpoint. The trial also reported significantly more problems with impairment of job performance on oxazepam than on passionflower (a 2007 Cochrane review classed this as an outcome not planned in advance and found it did not reach statistical significance in its own analysis). This finding — similar anxiety relief with fewer reported job-performance problems — is the central reason passionflower retains a place in clinical practice despite the much wider use of prescription benzodiazepines. The 2008 Movafegh pre-operative trial extended this to a different anxiety context: 60 patients undergoing ambulatory surgery received either passionflower extract 500 mg or placebo 90 minutes pre-operatively, and the passionflower group had significantly lower anxiety scores on a numerical rating scale over the 90 minutes after the dose. This page walks through the trial evidence, the practical clinical positioning, and the situations where passionflower is and is not the right anxiolytic choice.


Table of Contents

  1. The Akhondzadeh 2001 GAD Trial vs Oxazepam
  2. The Movafegh 2008 Pre-Operative Anxiety Trial
  3. Dental-Procedure Anxiety Trials
  4. The Anxiolytic Mechanism: Chrysin and Benzoflavones
  5. Situational vs Generalized Anxiety — Dosing Differences
  6. Why Cognitive Function Is Preserved
  7. Clinical Positioning Between Chamomile and Kava
  8. Practical Dosing, Forms, and Onset
  9. Combination Protocols (Lavender, Lemon Balm, L-Theanine)
  10. Cautions and Interactions
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The Akhondzadeh 2001 GAD Trial vs Oxazepam

The single most influential clinical trial of passionflower was conducted by Shahin Akhondzadeh and colleagues at the Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, and published in the Journal of Clinical Pharmacy and Therapeutics in 2001. The study was a double-blind randomized controlled trial designed to address a clinically important question: does an herbal anxiolytic match a standard benzodiazepine for generalized anxiety disorder?

Thirty-six outpatients meeting DSM-IV criteria for generalized anxiety disorder were randomized to either:

The double-blind design used dummy oxazepam tablets in the herbal arm and dummy passionflower drops in the benzodiazepine arm so that neither patients nor investigators knew which active treatment each subject was receiving. Anxiety was measured weekly with the Hamilton Anxiety Rating Scale (HAM-A), the gold-standard clinician-administered instrument for generalized anxiety severity. The trial report also describes problems with job performance; the 2007 Cochrane review that re-examined the trial describes job performance as a post-hoc outcome (one not planned before the trial began).

After four weeks, the results were:

The trial has been criticized for its small size (36 patients) and single-site design, and the dosing of the oxazepam arm (30 mg/day) is on the lower end of typical clinical practice. Even with those caveats, the clinical signal — equivalent anxiolysis with significantly less daytime impairment — has been remarkably durable and has been cited in essentially every subsequent review of herbal anxiolytics. The trial established passionflower's clinical credibility as a real option for generalized anxiety in patients who cannot tolerate benzodiazepine sedation.

What is not known: the only Cochrane review of passionflower for anxiety (Miyasaka 2007) found just two eligible randomized trials, with 198 people in total. It concluded that these trials are too few to draw any conclusions, and that larger trials comparing passionflower with placebo and with other medicines, including antidepressants, are needed.

Back to Table of Contents

The Movafegh 2008 Pre-Operative Anxiety Trial

The Movafegh 2008 study (Anesthesia & Analgesia) addressed a different but practically important anxiety context: the acute situational anxiety patients experience in the 90 minutes before surgery. This is normally treated with intravenous midazolam at the time of preoperative line placement, but oral premedication options that do not require intravenous (IV) access are clinically useful, particularly for outpatient procedures.

The trial randomized 60 patients undergoing ambulatory (same-day) surgery, 30 per group, to receive either:

Anxiety and sedation were scored on a numerical rating scale before the dose and 10, 30, 60 and 90 minutes after it. Psychomotor performance (Trieger Dot Test and Digit-Symbol Substitution Test) was tested on arrival in the operating room and 30 and 90 minutes after the breathing tube was removed (tracheal extubation, meaning the operations were done under general anesthesia). The time from arrival in the recovery unit to discharge home was also recorded.

Results:

The Movafegh trial established passionflower as a real option for outpatient pre-procedural anxiety where intravenous midazolam is not desired and where intact psychomotor function in the post-anesthesia recovery period matters — particularly for patients being discharged home shortly after surgery.

A separate 2012 trial by Aslanargun and colleagues in Turkey studied 60 patients aged 25-55 before spinal anesthesia, using the State-Trait Anxiety Inventory (STAI). Anxiety rose less between baseline and the moment just before spinal anesthesia in the passionflower group than in the placebo group, and passionflower did not change psychomotor test results, sedation level or hemodynamics (blood pressure and heart rate).

Back to Table of Contents

Dental-Procedure Anxiety Trials

The dental literature has produced multiple positive trials of passionflower for the specific context of dental-chair anxiety. Dental anxiety affects an estimated 9-15% of adults in industrialized populations to a degree that delays or prevents needed care, and benzodiazepines are routinely used as oral premedication for anxious patients undergoing extractions, periodontal surgery, and root canals.

Notable trials and reviews:

  1. Dantas LP et al. (2017) — a randomized, double-blind crossover trial in 40 volunteers who had both lower wisdom teeth (mandibular third molars) removed, one side at a time, receiving passionflower 260 mg or midazolam 15 mg by mouth 30 minutes before each surgery. Anxiety was assessed with questionnaires and with heart rate, blood pressure and oxygen saturation. There were no significant differences between the two in blood pressure, heart rate or oxygen saturation, and over 70% of volunteers said they felt quiet or only a little anxious with either drug. With midazolam, 20% reported amnesia (no memory of the procedure at all), while passionflower showed little or no effect on memory.
  2. Kaviani N et al. (2013) — a single-blind trial in 63 patients with moderate to severe anxiety who needed gum (periodontal) treatment, split into three groups of 21: passionflower drops, placebo drops, or no treatment. The mean anxiety score fell from 12.09 to 8.47 with passionflower, from 12.00 to 10.52 with placebo, and from 11.66 to 11.23 with no treatment; the passionflower group differed significantly from both other groups (p < 0.0001). The authors described it as a first study needing larger trials to confirm it.
  3. Christoffoli MT et al. (2021) — a randomized, double-blind, split-mouth crossover trial in 20 patients (mean age 22.5) having lower wisdom teeth removed, comparing passionflower with midazolam. Heart rate was best controlled with passionflower at one stage of surgery (p = 0.036), and side effects such as drowsiness, muscle relaxation and dizziness were reported more with midazolam.
  4. Lima Neto TJ et al. (2025) — 30 patients aged 16-35 having impacted wisdom teeth removed were randomly given passionflower, midazolam or placebo (10 per group) 30 minutes before surgery. Anxiety scores and most physical measures did not differ between the groups; diastolic blood pressure was higher with passionflower. After surgery, the stress hormone cortisol in saliva was significantly lower with both passionflower and midazolam than with placebo, with no difference between passionflower and midazolam.
  5. Araújo JO et al. (2021) — a systematic review of oral sedation for dental treatment in adults covered 12 randomized trials (327 patients): nine of benzodiazepines and three of herbal medicines. It found that midazolam 15 mg reduced anxiety more than passionflower 260 mg, while more patients reported side effects with midazolam 15 mg. The authors noted that the findings are limited by the quality of the included studies and that more trials are needed.

The clinical implication: passionflower has been tested head-to-head against benzodiazepines (oxazepam, midazolam) in two patient populations — generalized anxiety disorder and dental extraction — while the pre-surgical trials compared it with placebo. On anxiety, results range from no significant difference to a greater anxiety reduction with midazolam; memory loss, drowsiness and other side effects were reported less often with passionflower. The 2007 Cochrane review concluded that the randomized trials of passionflower for anxiety are too few in number to permit any conclusions.

Back to Table of Contents

The Anxiolytic Mechanism: Chrysin and Benzoflavones

The primary anxiolytic mechanism of passionflower is positive allosteric modulation of the gamma-aminobutyric acid-A receptor at the benzodiazepine binding site. This was originally demonstrated by Wolfman and colleagues in 1994 when they isolated chrysin (5,7-dihydroxyflavone) from Passiflora coerulea and showed it bound the central benzodiazepine receptor with measurable affinity. Chrysin is also present in Passiflora incarnata, along with apigenin (the chamomile flavone), luteolin, and other flavones that contribute to the overall flavonoid pool.

A second active scaffold was proposed in 2001 by Dhawan and colleagues: a fraction of the methanol extract of Passiflora incarnata was anxiolytic at 10 mg/kg in mice in the elevated plus maze, and they proposed that a compound with a benzoflavone core was responsible. Their later papers describe a tri-substituted benzoflavone moiety from the plant that was anxiolytic at 10 mg/kg by mouth in mice (animal studies only).

The combined effect of chrysin and benzoflavones at the gamma-aminobutyric acid-A benzodiazepine site is to potentiate the inhibitory effect of endogenous gamma-aminobutyric acid (GABA) — the same fundamental mechanism as diazepam or oxazepam, but with much lower binding affinity and partial-agonist character. The pharmacologic consequence is that passionflower amplifies normal GABAergic inhibition modestly rather than producing the powerful clamping effect of a full benzodiazepine agonist. This is why anxiety is reduced but cognition, motor coordination, and arousal are preserved.

For a full pharmacology discussion of the binding site, the harman alkaloids, and the theoretical MAO-A interaction, see the gamma-aminobutyric acid Modulation deep-dive page.

Back to Table of Contents

Situational vs Generalized Anxiety — Dosing Differences

The trial evidence supports passionflower for two distinct clinical contexts that require different dosing strategies:

The choice of formulation matters. Glycerin tinctures and aqueous teas extract a different flavonoid profile than ethanol tinctures or hydroethanolic dry extracts. The trials that produced positive results used standardized hydroethanolic extracts where the flavonoid content was characterized; bulk dried-leaf preparations of unknown extraction profile may not produce equivalent effect.

Back to Table of Contents

Why Cognitive Function Is Preserved

The repeated finding that passionflower reduces anxiety without impairing cognition or motor coordination is mechanistically explained by the partial-agonist, low-affinity binding profile at the gamma-aminobutyric acid-A benzodiazepine site. Full benzodiazepine agonists like diazepam or alprazolam occupy a high fraction of the available benzodiazepine binding sites at therapeutic doses, producing strong potentiation of gamma-aminobutyric acid-A current. The result is global cortical and brainstem inhibition — the anxiolytic effect is real, but so is the cognitive slowing, motor incoordination, amnestic effect, and sedation. With chronic use, downregulation of gamma-aminobutyric acid-A receptor density produces tolerance and physiologic dependence.

Passionflower's chrysin and benzoflavones bind the same site with much lower affinity. At therapeutic doses, only a small fraction of available benzodiazepine binding sites are occupied, and the partial-agonist character means even occupied receptors are only partially activated. The result is a modest amplification of basal GABAergic inhibition that is sufficient to reduce pathologic anxiety but insufficient to produce the global cortical depression of full benzodiazepine agonism. Cognition, attention, motor coordination, and arousal remain near baseline.

There is also no documented tolerance development with passionflower over weeks-to-months of clinical use, which fits the low-occupancy, partial-agonist binding profile. Discontinuation produces no documented withdrawal syndrome — another contrast with benzodiazepines, where abrupt discontinuation after sustained use causes rebound anxiety, insomnia, and in severe cases, seizures.

Back to Table of Contents

Clinical Positioning Between Chamomile and Kava

Passionflower occupies a specific niche in the botanical anxiolytic spectrum that is best understood by comparison with its closest neighbors:

For severe or treatment-resistant anxiety disorder, prescription pharmacotherapy — selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors (SNRIs), buspirone, or in selected cases benzodiazepines — remains the standard of care. Passionflower is not a replacement for these in patients with severe panic disorder, severe GAD with substantial functional impairment, or anxiety with comorbid major depressive disorder. It is a useful adjunct or first-line option for mild-to-moderate anxiety where benzodiazepine side effects are unacceptable.

Back to Table of Contents

Practical Dosing, Forms, and Onset

Standardized extract dosing, based on the published trial literature and the European Medicines Agency (EMA) monograph:

Onset of effect for acute anxiolysis is 30-60 minutes after an oral dose; peak effect at 60-120 minutes; duration of effect 4-6 hours per dose. For chronic generalized anxiety, expect initial subjective benefit within several days but full effect over 2-4 weeks of consistent daily dosing.

Quality matters substantially. The flavonoid content of dried passionflower herb varies widely depending on harvest timing, plant part (leaves vs whole aerial parts vs flowers), drying method, and storage. European Medicines Agency monograph products are standardized to flavonoid content (typically expressed as vitexin equivalents); these are the preferred preparations for clinical use. Bulk dried herb of unknown standardization may produce inconsistent effects.

Back to Table of Contents

Combination Protocols (Lavender, Lemon Balm, L-Theanine)

Passionflower combines well with several other gentle nervines for additive or complementary anxiolytic effect without crossing into benzodiazepine-level sedation:

For comprehensive natural approaches to anxiety, see our Natural Anxiety Relief page.

Back to Table of Contents

Cautions and Interactions

Back to Table of Contents

Key Research Papers

  1. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M (2001). Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26(5), 363-367. — PubMed PMID: 11679026
  2. Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M (2008). Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesthesia & Analgesia, 106(6), 1728-1732. — PubMed PMID: 18499602
  3. Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU (2012). Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. Journal of Anesthesia, 26(1), 39-44. — PubMed PMID: 22048283
  4. Dantas LP, de Oliveira-Ribeiro A, de Almeida-Souza LM, Groppo FC (2017). Effects of passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction. Medicina Oral Patologia Oral y Cirugia Bucal, 22(1), e95-e101. — PubMed PMID: 27918731
  5. Kaviani N, Tavakoli M, Tabanmehr M, Havaei R (2013). The efficacy of Passiflora Incarnata Linnaeus in reducing dental anxiety in patients undergoing periodontal treatment. Journal of Dentistry (Shiraz), 14(2), 68-72. — PubMed PMID: 24724122
  6. Miyasaka LS, Atallah AN, Soares BG (2007). Passiflora for anxiety disorder. Cochrane Database of Systematic Reviews, (1), CD004518. — PubMed PMID: 17253512
  7. Pittler MH, Ernst E (2003). Kava extract for treating anxiety. Cochrane Database of Systematic Reviews, (1), CD003383. — PubMed PMID: 12535473
  8. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH (1994). Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology Biochemistry and Behavior, 47(1), 1-4. — PubMed PMID: 7906886
  9. Dhawan K, Kumar S, Sharma A (2001). Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. Journal of Ethnopharmacology, 78(2-3), 165-170. — PubMed PMID: 11694362
  10. Dhawan K, Dhawan S, Chhabra S (2003). Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. Journal of Pharmacy & Pharmaceutical Sciences, 6(2), 215-222. — PubMed PMID: 12935433
  11. Grundmann O, Wähling C, Staiger C, Butterweck V (2009). Anxiolytic effects of a passion flower (Passiflora incarnata L.) extract in the elevated plus maze in mice. Pharmazie, 64(1), 63-64. — PubMed PMID: 19216234
  12. Soulimani R, Younos C, Jarmouni S, Bousta D, Misslin R, Mortier F (1997). Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Journal of Ethnopharmacology, 57(1), 11-20. — PubMed PMID: 9234160
  13. Akhondzadeh S, Mohammadi MR, Momeni F (2005). Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Therapy, 2(4), 609-614. (Not indexed in PubMed.)
  14. Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K (2020). Passiflora incarnata in neuropsychiatric disorders — a systematic review. Nutrients, 12(12), 3894. — PubMed PMID: 33352740
  15. Araújo JO, Bergamaschi CC, Lopes LC, Guimarães CC, de Andrade NK, Ramacciato JC, Motta RHL (2021). Effectiveness and safety of oral sedation in adult patients undergoing dental procedures: a systematic review. BMJ Open, 11(1), e043363. — PubMed PMID: 33495257
  16. Christoffoli MT, Bachesk AB, Farah GJ, Ferreira GZ (2021). Assessment of Passiflora incarnata L for conscious sedation of patients during the extraction of mandibular third molars: a randomized, split-mouth, double-blind, crossover study. Quintessence International, 52(10), 868-878. — PubMed PMID: 34076379
  17. Lima Neto TJ, Ribeiro NP, Souza MB, Freitas RN, Karande S, Mourão CF, Chaves-Neto AH, Faverani LP (2025). Effects of Passiflora incarnata on salivary biomarkers and anxiety in patients undergoing third molar extraction surgery. Scientific Reports, 15(1), 43616. — PubMed PMID: 41381570

PubMed Topic Searches

  1. PubMed: Passiflora GAD trials
  2. PubMed: Passiflora pre-op anxiety
  3. PubMed: Passiflora vs midazolam dental
  4. PubMed: Passiflora chrysin mechanism
  5. PubMed: Herbal vs benzodiazepine RCTs

Back to Table of Contents

Connections

Back to Table of Contents